期刊
CANCER DISCOVERY
卷 6, 期 6, 页码 664-679出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-16-0040
关键词
-
类别
资金
- NIH [R01CA165206, R01CA193776, R01CA102646, R01CA116660, K23GM110496]
- Pennsylvania Department of Health
- Leukemia and Lymphoma Society
- Jeffrey Jay Weinberg Memorial Foundation
- Children's Hospital of Philadelphia Hematologic Malignancy Research Fund
- Stand Up To Cancer-St. Baldrick's Pediatric Dream Team translational research [SU2C-AACR-DT1113]
- St. Baldrick's Foundation Scholar Awards
- Research Scholar Grant from the American Cancer Society [RSG-14-022-01-CDD]
Chimeric antigen receptor (CAR)-modified T-cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFN gamma, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. SIGNIFICANCE: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. (C) 2016 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据